E-Therapeutics PLC
LSE:ETX
E-Therapeutics PLC
LSE:ETX
Price:
9.4 GBX
-3.59%
Market Closed
Updated:
May 4, 2024
E-Therapeutics PLC
Operating Income
|
E-Therapeutics PLC
Operating Income Peer Comparison
Comparables:
CNTA
AUTL
BCYC
IMCR
GNS
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
E-Therapeutics PLC
LSE:ETX
|
Operating Income
-£10.2m
|
CAGR 3-Years
-52%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-7%
|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Operating Income
-$171.3m
|
CAGR 3-Years
-154%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Operating Income
-$175.5m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Operating Income
-$179.9m
|
CAGR 3-Years
-47%
|
CAGR 5-Years
-52%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Operating Income
-£59.6m
|
CAGR 3-Years
13%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Operating Income
£53m
|
CAGR 3-Years
8%
|
CAGR 5-Years
4%
|
CAGR 10-Years
4%
|
See Also
What is E-Therapeutics PLC's Operating Income?
Operating Income
-10.2m
GBP
-10.2m
GBP
Based on the financial report for Jan 31, 2023, E-Therapeutics PLC's Operating Income amounts to -10.2m GBP.
What is E-Therapeutics PLC's Operating Income growth rate?
Operating Income CAGR 10Y
-7%
-7%
Over the last year, the Operating Income growth was -7%. The average annual Operating Income growth rates for E-Therapeutics PLC have been -52% over the past three years , -9% over the past five years , and -7% over the past ten years .
You don't have any saved screeners yet
